ArticleInternal medicine (Tokyo, Japan)2024
Dysbiosis of Gut Microbiota in Patients with Chronic Kidney Disease.
Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Oral dysbiosis in children with renal failure: a systematic review.Frontiers in dental medicine · 2026Pooled it
- Iron, ESA, and HIF-Inhibitors: Are There Other Opportunities to Improve Anemia of CKD?Journal of clinical medicine · 2026Review
- Research advancement on the correlation between gut microbiota and chronic kidney disease.Antonie van Leeuwenhoek · 2026Review
- Urinary Tract Infection in Patients with Urolithiasis: A Large Retrospective Observational Study of Clinical Features and Microbiological Spectrum.Pathogens (Basel, Switzerland) · 2026Observational
- Latent profile analysis of oral health self-efficacy in maintenance hemodialysis patients and its impact on oral health.Frontiers in public health · 2026Article
- Unraveling the oral microbiome's role in Alzheimer's disease: From pathophysiology to therapeutic potential.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Beyond Infection: How Antimicrobial Therapies Influence the Urinary Microbiome and Stone Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Inflammatory Biomarkers and Oral Health Disorders as Predictors of Head and Neck Cancer: A Retrospective Longitudinal Study.International journal of molecular sciences · 2025Article
- Unraveling the mysteries of the gut-kidney axis: the protective role of traditional Chinese medicine in chronic kidney disease.Frontiers in microbiology · 2025Review
- Association between oral microbiome diversity and kidney stones: a cross-sectional study.Frontiers in microbiology · 2025Article
- Propionate and butyrate counteract renal damage and progression to chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Gut Microbiota in Patients Receiving Dialysis: A Review.Pathogens (Basel, Switzerland) · 2024Review
- Causal Relationships Between Gut Microbiota, Metabolites, and Diabetic Nephropathy: Insights from a Two-Sample Mendelian Randomization Analysis.International journal of nephrology and renovascular disease · 2024Article
- Application of Mendelian randomization to assess host gene-gut microbiota correlations in patients with esophageal cancer.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The gut bacterial microbiota is altered in patients with chronic kidney disease (CKD). However, the bacterial composition at each stage of CKD is unclear in these patients, including those receiving renal replacement therapy. We herein report the changes in the gut microbiota among patients with CKD. Methods A total of 93 individuals were recruited for the study. Seventy-three patients had stage 3-5 CKD, including those receiving renal replacement therapy (CKD group), and 20 were age- and sex-matched controls (CKD stage 1-2). The gut microbiome composition was analyzed using a 16S ribosomal RNA gene-based sequencing protocol. Results At the genus level, the butyrate-producing bacteria Lachnospira, Blautia, Coprococcus, Anaerostipes, and Roseburia were more abundant in the control group (linear discriminant analysis score of >3) than in the CKD group. Lachnospira was more abundant in the control group than in patients with CKD stage 3a. Compared to the control group, multiplex butyrate-producing bacteria were deficient in patients with CKD stage 3b-5D, including in patients receiving renal replacement therapy. Conclusion Our findings highlight the fact that the gut bacterial composition, including butyrate-producing bacteria, deteriorates from CKD stage 3b. Even after renal replacement therapy, the bacterial composition did not change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.